Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 

 

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 

 

Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas for stock traders, including  biotech  and medical tech stocks reports on trading and news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a day’s high of $0.75 as of this report.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2025/biotech/01291Medical-Therapeutic-Stock-AEMD.asp

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

Recent news release

https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

Biotech stocks to watch:

Research more Biotech and medical technology stocks with Investorideas.com free stock directory

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: This news alert for AEMD is part of Investorideas.com paid content on behalf of Aethlon Medical. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more.. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, IR, PR and social media, podcast sponsorship and ticker tag content creation services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about digital advertising and guest posts/sponsored posts

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

 

Contact Investorideas.com

800 665 0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital

 

Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies

 

SAN DIEGO, CA- January 29, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news featuring AEMD in full at https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The Hemopurifier is an extracorporeal device that is used in concert with a blood pump. The device incorporates plasma separation, size exclusion, and affinity binding to an affinity resin containing a plant lectin. Mannose on the surface of enveloped viruses and extracellular vesicles binds to the plant lectin within the device. Extracellular vesicles released from solid tumors have been implicated in the spread of cancers known as metastasis as well as in the resistance to immunotherapy and chemotherapeutic agents. Removal of enveloped viruses and extracellular vesicles has been observed in in vitro studies and in human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard-of-care therapy. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a publicly traded medical device company based in San Diego, California. The company aims to leverage its therapeutic device, The Hemopurifier, to remove enveloped viruses and extracellular vesicles from biologic fluids. Aethlon Medical's innovative platform is enabling the development of new options for cancer and life-threatening infectious diseases. For more information on Aethlon Medical, Inc. and its clinical development program, visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the number of patients who receive pembrolizumab or nivolumab that will have lasting clinical responses to these agents; the possibility of novel treatment strategies; how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors; the efficacy of continued clinical trials. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: 

https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

New Stocks to Watch in Tech, Biotech, Mining and Nano; (Nasdaq: $SVCO), (NASDAQ: $RUM), (NYSE: $CLS; TSX: $CLS.TO), (Nasdaq: $PONY), (Nasdaq: $APP), (Nasdaq: $QSI), (CSE: $LINE.CN), (OTCQB: $DTZNY; ASX: DTZ)

 New Stocks to Watch in Tech, Biotech, Mining and Nano; (Nasdaq: $SVCO), (NASDAQ: $RUM), (NYSE: $CLS; TSX: $CLS.TO), (Nasdaq: $PONY), (Nasdaq: $APP), (Nasdaq: $QSI), (CSE: $LINE.CN), (OTCQB: $DTZNY; ASX: DTZ) 

 

 

 

January 24, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Tech, Biotech, Mining and Nano sectors.

 

The newest tech companies are involved in the AI, cloud and semiconductor sectors.

 

The latest biotech company works in proteomics, while the newest mining company explores North American mineral prospects.

 

The latest nanotechnology company develops climate and industrial nano-technologies..

 

New stocks added today: Silvaco Group, Inc. (Nasdaq: SVCO), Rumble Inc. (NASDAQ:RUM), Celestica Inc. (NYSE:CLS; TSX:CLS), Pony AI Inc. (Nasdaq: PONY), AppLovin Corporation (Nasdaq:APP), Quantum-Si Incorporated (Nasdaq: QSI), Linear Minerals Corp. (CSE: LINE), Dotz Nano Ltd. (OTCQB: DTZNY; ASX: DTZ) 

 

Read this in full at https://www.investorideas.com/news/2025/main/01241Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Tech Directories:

Silvaco Group, Inc. (Nasdaq: SVCO) is a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation. Silvaco’s solutions are used for semiconductor and photonics processes, devices, and systems development across display, power devices, automotive, memory, high performance compute, foundries, photonics, internet of things, and 5G/6G mobile markets for complex SoC design. Silvaco is headquartered in Santa Clara, California, and has a global presence with offices located in North America, Europe, Brazil, China, Japan, Korea, Singapore, and Taiwan.

 

Rumble Inc. (NASDAQ:RUM) is a high-growth video platform and cloud services provider that is creating an independent infrastructure. Rumble’s mission is to restore the internet to its roots by making it free and open once again.

 

Celestica Inc. (NYSE:CLS; TSX:CLS) enables the world's best brands. Through our recognized customer-centric approach, we partner with leading companies in Aerospace and Defense, Communications, Enterprise, HealthTech, Industrial and Capital Equipment to deliver solutions for their most complex challenges. As a leader in design, manufacturing, hardware platform and supply chain solutions, Celestica brings global expertise and insight at every stage of product development - from the drawing board to full-scale production and after-market services. With talented teams across North America, Europe and Asia, we imagine, develop and deliver a better future with our customers

 

Pony AI Inc. (Nasdaq: PONY) is a global leader in the large-scale commercialization of autonomous mobility. Leveraging its vehicle-agnostic Virtual Driver technology – a full-stack autonomous driving technology that seamlessly integrates its proprietary software, hardware, and services, Pony.ai is developing a commercially viable and sustainable business model that enables the mass production and deployment of vehicles across transportation use cases. Founded in 2016, Pony.ai has expanded its presence across China, Europe, East Asia, the Middle East, and other regions, ensuring widespread accessibility to its advanced technology. Pony.ai is among the first in China to obtain licenses to operate fully driverless vehicles in all four Tier-1 cities in China (Beijing, Guangzhou, Shanghai, Shenzhen) and has begun to offer public-facing, fare-charging robotaxi services without safety drivers in Beijing, Guangzhou and Shenzhen. Pony.ai operates a fleet consisting of over 250 robotaxis. To date, Pony.ai has driven nearly 40 million autonomous testing and operation kilometers (nearly 24.8 million miles) on open roads worldwide.

 

AppLovin Corporation (Nasdaq:APP) makes technologies that help businesses of every size connect to their ideal customers. The company provides end-to-end software and AI solutions for businesses to reach, monetize and grow their global audiences.

 

New Stocks Added to the Biotech Directories:

Quantum-Si Incorporated (Nasdaq: QSI) The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools.

 

New Stocks Added to the Mining Directories:

Linear Minerals Corp. (CSE: LINE) - Formerly FE Battery Metals Corp - is a publicly traded Canadian mineral exploration company with a primary focus of acquiring a multi-commodity mineral property portfolio. Our goal is to identify, acquire and explore North American mineral prospects in the precious metal, base metal, and industrial metals sector.

 

New Stocks Added to the Nanotech Directories:

Dotz Nano Ltd. (OTCQB: DTZNY; ASX: DTZ) is a nanotechnology company developing innovative climate and industrial nano-technologies. The Company’s primary focus is centered around ground-breaking carbon dioxide (CO2) management technologies leading towards carbon-neutral future. The Company’s proprietary carbon-based solid sorbent, offering an efficient and sustainable approach, facilitating industrial deep decarbonization.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

 

 

 

 

Healthcare Investors Take Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) to NASDAQ Top Percentage Gainers List

Healthcare Investors Take Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) to NASDAQ Top Percentage Gainers List: Healthcare Investors Take Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) to NASDAQ Top Percentage Gainers List

Biomedical Stock Biomerica Inc. (NASDAQ: BMRA) Makes NASDAQ TOP Gainer List on UAE Ministry of Health and Prevention Approval

Biomedical Stock Biomerica Inc. (NASDAQ: BMRA) Makes NASDAQ TOP Gainer List on UAE Ministry of Health and Prevention Approval: Biomedical Stock Biomerica Inc. (NASDAQ: BMRA) Makes NASDAQ TOP Gainer List on UAE Ministry of Health and Prevention Approval

IPOs in Tech, Biotech and Mining; (NASDAQ: $HIT), (NASDAQ: $NTCL), (NASDAQ: $TTAN), (NASDAQ: $NAMI), (Nasdaq: $ZSPC), (Nasdaq: $JUNS), (NASDAQ: $AVR), (CSE: $KENY.CN)

 IPOs in Tech, Biotech and Mining; (NASDAQ: $HIT), (NASDAQ: $NTCL), (NASDAQ: $TTAN), (NASDAQ: $NAMI), (Nasdaq: $ZSPC), (Nasdaq: $JUNS), (NASDAQ: $AVR), (CSE: $KENY.CN)

 

 

 

 

January 10, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the tech, Biotech and Mining sectors.

 

New companies are all recent IPOs on the Nasdaq, NYSE or CSE exchanges.

 

New stocks added today: Health In Tech, Inc. (NASDAQ:HIT), NetClass Technology Inc (NASDAQ:NTCL), ServiceTitan, Inc. (NASDAQ:TTAN), Jinxin Technology Holding Co (NASDAQ:NAMI), zSpace, Inc. (Nasdaq:ZSPC), JUPITER NEUROSCIENCES, INC. (Nasdaq:JUNS), Anteris Technologies Global Corp. (NASDAQ:AVR), Makenita Resources Inc. (CSE: KENY).

 

Read this in full at https://www.investorideas.com/news/2025/main/01101IPOs.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Tech Directories:

Health In Tech, Inc. (NASDAQ:HIT) is an Insurtech platform company backed by third-party AI technology. We offer a dynamic marketplace designed to create customized healthcare plan solutions while streamlining processes through vertical integration, process simplification, and automation. By eliminating friction and complexities, HIT enhances value propositions for employers and optimizes underwriting, sales, and service workflows for Managing General Underwriters (MGUs), insurance carriers, licensed brokers, and Third-Party Administrators (TPAs).

 

NetClass Technology Inc (NASDAQ:NTCL) is a leading B2B smart education specialist with offices in Shanghai, Hong Kong, and Singapore, providing innovative IT solutions to schools, training institutions, corporations, public agencies, and other organizations. Our services include SaaS subscription services and application software development, with solutions spanning teaching and campus management, online teaching, examinations, epidemic prevention, data storage, EDC (Education Credit) blockchain systems, and lecturer evaluation services. Our mission is to deliver reliable, high-quality products that drive sustainable growth for our customers.

 

ServiceTitan, Inc. (NASDAQ:TTAN) is the software platform that powers trades businesses. The company’s cloud-based, end-to-end solution gives contractors the tools they need to run and grow their business, manage their back office, and provide a stellar customer experience. By bringing an integrated SaaS platform to an industry historically underserved by technology, ServiceTitan is equipping tradespeople with the technology they need to keep the world running.

 

Jinxin Technology Holding Co (NASDAQ:NAMI) Headquartered in Shanghai, China, Jinxin Technology Holding Company is an innovative digital content service provider in China. Leveraging the powerful digital content generation engine powered by advanced AI/AR/VR/digital human technologies, the Company is committed to offering users high-quality digital content services through both its own platform and the content distribution channels of its strong partners. According to Frost & Sullivan, the Company was the largest digital textbook platform in China in terms of revenue in 2022, with a market share of 12.7%.  The Company currently target K-9 students in China, with core expertise in providing them digital and integrated educational contents, and plan to further expand service offerings to provide premium and engaging digital contents to other age groups. The Company collaborates with leading textbook publishers in China and provides digital version of mainstream textbooks used in primary schools and middle schools. The Company's AI-generated content technology enables comprehensive digital contents to deliver an interactive, intelligent and entertaining learning experience. The Company distributes digital contents primarily through (i) its flagship learning app, Namibox, (ii) telecom and broadcast operators and (iii) third-party devices with our contents embedded

 

zSpace, Inc. (Nasdasq:ZSPC) delivers innovative augmented and virtual reality (AR/VR) experiences for STEM, CTE, and career readiness programs. Used by over 3,500 public school districts, technical centers, community colleges, and universities, zSpace allows students and teachers to experience learning in the classroom that may otherwise be dangerous, impossible, counterproductive, or expensive using traditional techniques. Headquartered in San Jose, California, zSpace holds over 70 patents and our hands-on “learning by doing” solutions have been shown to enhance the learning process and drive higher student test scores, as evidenced by a study on the utility of 3D virtual reality technologies for student knowledge gains published in the Journal of Computer Assisted Learning in 2021.

 

New Stocks Added to the Biotech Directories:

JUPITER NEUROSCIENCES, INC. (Nasdasq:JUNS) is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS.

 

Anteris Technologies Global Corp. (NASDAQ:AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR® Transcatheter Heart Valve ("THV"), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.

 

New Stocks Added to the Mining Directories:

Makenita Resources Inc. (CSE: KENY) is a junior resource exploration company focused on the Hector Silver/Cobalt Project in Ontario Canada.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411